|
1
|
Matsuda T, Marugame T, Kamo KI, Katanoda
K, Ajiki W and Sobue T; The Japan Cancer Surveillance Research
Group. Cancer incidence and incidence rate in Japan in 2006: Based
on data from 15 population-based cancer registries in the
monitoring of cancer incidence in Japan (MCIJ) project. Japn J Clin
Oncol. 42:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomas T and Thomas TJ: Polyamines in cell
growth and cell death: molecular mechanisms and therapeutic
applications. Cell Mol Life Sci. 58:244–258. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Russell DH: Increased polyamine
concentrations in the urine of human cancer patients. Nat New Biol.
223:144–145. 1971. View Article : Google Scholar
|
|
4
|
Löser C, Fölsch UR, Paprotny C and
Creutzfeldt W: Polyamines in colorectal cancer, evaluation of
polyamine concentrations in colon tissue, serum and urine of 50
patients with colorectal cancer. Cancer. 65:958–966. 1990.
|
|
5
|
Bachrach U: Polyamines as markers of
malignancy. Prog Drug Res. 39:9–33. 1992.
|
|
6
|
Hiramatsu K, Sugimoto M, Kamei S,
Kinoshita K, Iwasaki K and Kawakita M: Determination of the amounts
of polyamines excreted in urine: determination of
N1,N8-diacetylspermidine and
N1,N12-diacetylspermine as components
commonly occurring in normal human urine. J Biochem. 117:107–112.
1995.PubMed/NCBI
|
|
7
|
Hiramatsu K, Sugimoto M, Kamei S, Hoshino
M, Kinoshita K, Iwasaki K and Kawakita M: Diagnostic and prognostic
usefulness of N1,N8-diacetylspermidine and
N1,N12-diacetylspermine in urine as novel markers of malignancy. J
Cancer Res Clin Oncol. 123:539–545. 1997.
|
|
8
|
Hiramatsu K, Miura H, Kamei S, Iwasaki K
and Kawakita M: Development of a sensitive and accurate
enzyme-linked immunosorbent assay (ELISA) system that can replace
HPLC analysis for determination of
N1,N12-diacetylspermine in human urine. J
Biochem. 124:231–236. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamaoki M, Hiramatsu K, Suzuki S, Nagata A
and Kawakita M: Two enzymed-linked immunosorbent assay (ELISA)
systems for N1,N8-diacetylspermidine and
N1,N12-diacetylspermine using monoclonal
antibodies. J Biochem. 132:783–788. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiramatsu K, Takahashi K, Yamaguchi T,
Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M,
Kawaguchi M, Toi M, Mori T and Kawakita M:
N1,N12- diacetylspermine as a sensitive and
specific novel marker for early- and late-stage colorectal and
breast cancers. Clin Cancer Res. 11:2986–2990. 2005.
|
|
11
|
Umemori Y, Kuribayashi K, Tsuji N,
Nishidate T, Kameshima H, Hirata K and Watanabe N: Evaluating the
utility of N1,N12- diacetylspermine and
N1,N8-diacetylspermidine in urine as tumor
markers for breast and colorectal cancers. Clin Chim Acta.
411:1894–1899. 2010.
|
|
12
|
Enjoji M, Nakamuta E, Arimura E, Morizono
S, Kuniyoshi M, Fukushima M, Kotoh K and Nawata H: Clinical
significance of urinary
N1,N12-diacetylspermine levels in patients
with hepatocellular carcinoma. Int J Biol Markers. 19:322–327.
2004.
|
|
13
|
Kawakita M, Hiramatsu K, Yanagiya M, Doi Y
and Kosaka M: Determination of N1,N12-diacetylspermine in urine: a
novel tumor marker. Methods Mol Biol. 720:367–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samejima K, Hiramatsu K, Takahashi K,
Kawakita M, Kobayashi M, Tsumoto H and Kohda K: Identification and
determination of urinary acetylpolyamines in cancer patients by
electrospray ionization and time-of-flight mass spectrometry. Anal
Biochem. 401:22–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer (UICC) TNM Classification Of
Malignant Tumors. 7th edition. Wiley-Liss; New York, NY: 2010
|
